{
  "docId": "019de070-8dac-72dd-8b30-47dcdd26ea78",
  "docSlug": "14b2a339e11f22ed5b817a794c035302",
  "documentTitle": "Chimerix | Mergers and Acquisitions Presentation Deck | 26 slides",
  "authorId": "chimerix",
  "authorName": "Chimerix",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 6,
  "pageCount": 26,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "dense",
  "nDataPoints": 3,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-8dac-72dd-8b30-47dcdd26ea78/6",
  "deckHref": "/decks/019de070-8dac-72dd-8b30-47dcdd26ea78",
  "deckJsonHref": "/decks/019de070-8dac-72dd-8b30-47dcdd26ea78.json",
  "deckAnchorHref": "/decks/019de070-8dac-72dd-8b30-47dcdd26ea78#slide-6",
  "components": [
    {
      "bbox": {
        "h": 0.28,
        "w": 0.92,
        "x": 0.04,
        "y": 0.26
      },
      "kind": "list",
      "text": "Market research: Nearly all mid-line glioma patients tested for H3 K27M-mutation; Oncologists consider ~20% ORR clinically meaningful; ONC201 use expected in >80% of patients; Interest in combination with radiation",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "04d4e924-f880-43be-b58d-bc324a595682",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.92,
        "x": 0.04,
        "y": 0.7
      },
      "kind": "list",
      "text": "Low barriers to adoption: No effective treatment options available; K27M already on commercial and site-specific NGS panels, oral dosing (QW), good safety profile; High unaided awareness of ONC201; Potential combinable with other therapies",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a2673dfa-68a9-44eb-8410-a34a66fea6fd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.92,
        "x": 0.04,
        "y": 0.56
      },
      "kind": "list",
      "text": "Competitive landscape: chemotherapy and bevacizumab ineffective; targeted agents, vaccines and CAR-T therapies are in early development with limited efficacy analysis available",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d1bef36d-cd5a-48e3-84ea-38891bb08b21",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.92,
        "x": 0.04,
        "y": 0.16
      },
      "kind": "list",
      "text": "Addressable market: U.S. incidence (annual): ~2,000",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "faf2196f-de81-43d4-ac45-7c70634dc468",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.11,
        "w": 0.92,
        "x": 0.04,
        "y": 0.04
      },
      "kind": "title",
      "text": "H3 K27M-mutant glioma: market dynamics and opportunity",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "468d2210-beeb-4c97-ac0b-33da4a1ff430",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Market Segmentation Pyramid",
      "slug": "market-segmentation-pyramid",
      "agent": null,
      "layer": "slide",
      "matchId": "c7a472db-7ea6-45f4-b8c6-583017bb5ac3",
      "evidence": "The slide discusses market dynamics and opportunity, including addressable market size.",
      "confidence": 0.6
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}